Eterna Therapeutics

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

NTN Buzztime, Inc. is a provider of interactive entertainment and technology, primarily serving bars, restaurants, casinos, and senior living centers in the United States and Canada. Founded in 1982 and based in Carlsbad, California, the company offers a tablet platform that features a variety of games, including trivia, card, and sports games. NTN Buzztime generates revenue through subscription fees from network subscribers, leasing equipment such as tablets, and selling advertising for in-venue displays. The company also licenses its content for use on third-party equipment. With a focus on social entertainment, NTN Buzztime has over 4 million registered players participating in more than 50 million games annually. It has recently launched BEOND, a mobile entertainment platform designed to enhance the customer experience in bars and restaurants. As of mid-2020, NTN Buzztime served over 1,200 venues through its interactive entertainment network.

IRX Therapeutics develops immune therapies designed to activate a patient’s immune system to defeat cancer and related diseases. IRX Therapeutics’ is focused on making cancer treatments better. The lead platform technology, IRX-2, is thought to broadly restore the immune system by overcoming cancer-induced immune suppression. The Company believes that its products can play an important role in helping a wide range of cancer treatments improve and extend the lives of patients. It was founded in 1994 and is headquartered in New York.